Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. (Q47414856)

15 January 2018

meta-analysis

0 references

title

Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. (English)

1 reference

15 January 2018

author

Stephen Faraone

series ordinal

1

1 reference

15 January 2018

publication date

13 September 2010

1 reference

15 January 2018

Journal of Attention Disorders

published in

1 reference

15 January 2018

volume

16

1 reference

15 January 2018

page(s)

128-137

1 reference

15 January 2018

issue

2

1 reference

15 January 2018

Methyiphenidate vs. amphetamine: Comparative review

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1087054710379738

21 January 2018

Identifiers

DOI

10.1177/1087054710379738

1 reference

15 January 2018

PubMed ID

20837983

1 reference

15 January 2018